Nutex Health Inc. (NUTX) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — NUTX

Balance Sheet

(in millions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	205.21	207.35	166.05	96.73	84.73	46.91	40.81	30.01	26.83	32.75	32.84	36.62	47.60	12.72	6.01	4.80	3.74
Accounts Receivable	--	--	--	--	295.08	62.75	60.66	61.53	53.21	50.68	50.98	61.48	94.65	0.79	0.43	0.33	0.35
Inventory	4.21	4.68	3.16	2.28	3.12	2.26	2.76	2.98	2.68	2.45	3.49	3.21	2.91	--	--	--	--
Total Current Assets	585.65	579.65	592.65	473.03	401.52	119.80	113.87	100.36	89.85	92.08	88.67	107.54	148.98	14.97	11.61	5.59	4.16
Property, Plant & Equipment	95.70	94.93	82.82	82.92	76.43	78.25	78.88	80.57	85.50	83.06	77.12	72.28	67.82	0.01	0.01	0.01	0.01
Goodwill	13.92	13.92	13.92	13.92	13.92	13.92	13.92	17.07	17.94	17.01	17.01	17.01	425.36	57.89	54.70	55.18	54.98
Intangible Assets	13.58	13.91	14.56	14.88	15.21	15.86	16.18	20.10	21.62	20.42	20.80	21.58	21.96	10.37	9.27	9.46	9.65
Total Non-current Assets*	378.98	377.67	371.87	368.00	360.40	318.69	308.53	303.93	389.78	344.16	341.43	326.98	722.81	68.36	71.66	71.77	71.78
Total Assets	964.63	957.32	964.52	841.03	761.92	438.49	422.40	404.28	479.63	436.23	430.10	434.52	871.79	83.33	83.27	77.36	75.94
Accounts Payable	--	--	--	--	19.84	10.32	16.74	17.22	17.60	16.42	15.05	17.74	19.95	3.68	3.33	3.81	4.34
Short-term Debt	--	--	--	--	--	--	--	--	--	--	--	31.42	26.74	--	--	--	--
Total Current Liabilities	117.22	184.44	185.46	194.87	196.18	67.56	71.66	59.89	67.27	57.44	47.88	43.83	56.47	8.43	6.53	7.28	6.94
Long-term Debt	31.11	24.26	25.57	20.46	21.73	26.80	22.41	26.31	19.30	25.11	25.11	24.69	16.31	--	--	--	0.00
Total Non-current Liabilities*	340.10	330.83	341.03	309.28	310.47	291.15	268.72	264.38	307.46	270.56	272.68	258.16	248.91	1.79	2.80	2.81	2.73
Total Liabilities	457.32	515.27	526.49	504.15	506.65	358.71	340.38	324.27	374.73	328.01	320.56	301.99	305.38	10.22	9.33	10.09	9.67
Retained Earnings	(173.54)	(239.38)	(298.02)	(353.46)	(335.76)	(418.59)	(409.80)	(409.44)	(377.45)	(371.91)	(368.43)	(358.97)	57.64	(48.65)	(27.31)	(25.40)	(22.66)
Total Stockholder Equity*	394.32	346.29	317.17	235.25	176.95	60.44	62.73	63.02	89.93	92.62	92.62	110.49	525.69	73.11	73.94	67.26	66.26

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Total Revenue	210.75	216.49	151.68	267.80	243.99	211.79	257.62	78.79	76.08	67.45	69.67	62.72	58.92	56.33	126.64	29.00	58.05	6.21	5.92	5.57
Cost of Revenue*	69.47	124.76	105.54	112.92	119.06	93.45	115.99	56.88	53.52	57.30	56.46	55.66	49.28	51.48	93.43	55.47	53.06	4.49	4.49	4.38
Gross Profit	141.28	91.73	46.14	154.88	124.92	118.34	141.63	21.92	22.56	10.16	13.21	7.07	9.65	4.85	33.21	(26.47)	4.99	1.72	1.43	1.19
Research & Development	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	0.07	0.08	0.07
Selling, General & Admin	16.68	14.38	17.82	11.30	12.50	10.04	12.75	9.87	10.65	8.66	8.50	7.79	9.76	7.18	(6.31)	4.08	2.49	17.78	4.23	1.74
Total Operating Expenses	19.56	10.47	15.22	24.51	91.25	37.68	27.34	12.25	17.26	8.71	39.36	7.89	10.01	9.29	(16.95)	412.54	6.37	18.08	4.54	2.01
Operating Income	121.72	81.27	30.92	130.37	33.68	80.66	114.29	9.66	5.30	1.45	(26.14)	(0.82)	(0.36)	(4.45)	50.16	(439.01)	(1.38)	(16.37)	(3.11)	(0.82)
Interest Expense	--	--	--	--	--	--	--	--	--	4.44	4.24	4.10	4.84	3.14	2.86	3.40	3.85	--	--	1.56
Pretax Income	117.09	76.56	25.89	123.94	23.73	71.22	108.65	(2.58)	3.90	(0.15)	(30.71)	(4.87)	(5.08)	(7.83)	42.54	(441.78)	(3.82)	(16.58)	(5.58)	(1.80)
Tax Provision	20.77	13.80	9.29	27.14	7.59	20.41	9.15	4.58	0.89	0.39	(3.00)	(0.34)	(0.82)	(0.91)	1.99	(8.54)	19.65	(0.01)	(1.92)	--
Net Income	65.84	46.81	11.83	55.44	(17.70)	21.22	61.61	(8.79)	(0.36)	(0.36)	(31.62)	(5.54)	(3.48)	(5.15)	48.51	(433.24)	(23.48)	(16.57)	(4.63)	(1.80)
Basic EPS	9.58	6.70	3.16	8.27	(2.95)	3.74	12.05	(1.72)	(0.07)	(0.01)	(0.04)	(0.01)	(0.01)	(0.01)	0.00	(0.65)	(0.03)	--	--	--
Diluted EPS	9.38	6.52	3.11	7.76	(2.95)	3.33	11.51	(1.72)	(0.07)	(0.01)	(0.04)	(0.01)	(0.01)	(0.01)	0.00	(0.65)	(0.03)	--	--	--

* Derived from reported values

Cash Flow Statement

(in millions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Operating Cash Flow	34.20	75.52	70.39	99.51	27.26	50.97	0.05	6.79	13.26	3.05	(1.78)	1.97	0.01	1.05	4.51	(7.30)	55.78	(2.38)	(2.73)	(1.58)
Capital Expenditures	2.54	1.20	1.41	0.30	0.75	0.06	0.40	0.62	0.56	0.73	(0.83)	2.88	3.07	4.38	(7.88)	5.89	21.71	0.00	--	--
Free Cash Flow*	31.66	74.32	68.98	99.21	26.51	50.90	(0.34)	6.17	12.70	2.32	(0.95)	(0.91)	(3.06)	(3.32)	12.39	(13.19)	34.07	(2.38)	--	--
Investing Cash Flow	(2.54)	(1.20)	(5.07)	(0.30)	0.20	(0.06)	(3.34)	(0.27)	(1.27)	(0.73)	0.87	(3.62)	(3.07)	(5.42)	7.88	(5.89)	(6.14)	(0.18)	5.16	(1.09)
Financing Cash Flow	(35.19)	(49.55)	(45.79)	(29.90)	(15.45)	(6.81)	(2.99)	(0.42)	(1.19)	5.69	(3.91)	(4.28)	2.98	2.95	(14.75)	2.21	(35.56)	(0.04)	6.88	3.89

* Derived from reported values